Metraipolis › archive › dc_5cbffbc99e3a
Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 — Europe PMC PPR:PPR202795
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR202795
- DOI
- 10.1101/2020.08.18.255877
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-07T17:10:07.806Z
- SHA-256 of the archived text
eb3b09495f3c5584b66eb6e15fe7cac4d7e81cd658eab7f8ca5ab51f2a02d2e4- Stable URL of this page
https://metraipolis.com/documento/dc_5cbffbc99e3a
How to cite
Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 — Europe PMC PPR:PPR202795 — Europe PMC, https://europepmc.org/article/PPR/PPR202795 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_5cbffbc99e3a (Metraipolis archive dc_5cbffbc99e3a, sha256 eb3b09495f3c5584b66eb6e15fe7cac4d7e81cd658eab7f8ca5ab51f2a02d2e4)
BibTeX
@misc{dc5cbffbc99e3a,
title = {Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 — Europe PMC PPR:PPR202795},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR202795},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_5cbffbc99e3a; sha256 eb3b09495f3c5584b66eb6e15fe7cac4d7e81cd658eab7f8ca5ab51f2a02d2e4},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR202795. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Drug repurposing is a rapid approach to identifying therapeutics for the treatment of emerging infectious diseases such as COVID-19. To address the urgent need for treatment options, we carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products. Three hundred and nineteen compounds with anti-SARS-CoV-2 activities were identified and confirmed, including 91 approved drug and 49 investigational drugs. Among these confirmed compounds, the anti-SARS-CoV-2 activities of 230 compounds, including 38 approved drugs, have not been previously reported. Chlorprothixene, methotrimeprazine, and piperacetazine were the three most potent FDA approved drugs with anti-SARS-CoV-2 activities. These three compounds have not been previously reported to have anti-SARS-CoV-2 activities, although their antiviral activities against SARS-CoV and Ebola virus have been reported. These results demonstrate that this comprehensive data set of drug repurposing screen for SARS-CoV-2 is useful for drug repurposing efforts including design of new drug combinations for clinical trials. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: bioRxiv, 2020 (prima pubblicazione 2020-08-18). Identificativi: DOI 10.1101/2020.08.18.255877. Pagina: https://europepmc.org/article/PPR/PPR202795 — https://doi.org/10.1101/2020.08.18.255877. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-07T17:05:59.008Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.